Search

everythinglearnresearchcommunity

for

Search:↓

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Tofacitinib treatment is used for teenagers with alopecia areata.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Radiesse is a versatile facial injectable used for cosmetic improvements and long-term collagen production, with careful dosing needed to prevent complications.

Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.

In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Upadacitinib may effectively treat resistant lichen planopilaris.

TAK-279 effectively reduces psoriasis symptoms and is safe.